A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Methamphetamine-associated psychosis (MAP) has been considered a pharmacological or
environmental pathogen model of schizophrenia (SCZ) due in part to similarities in clinical
presentation (i.e. paranoia, hallucinations, disorganized speech, and negative symptoms),
response to treatment (e.g.neuroleptics),and pathologic mechanisms (e.g. central dopaminergic
neurotransmission) of both conditions. Both risperidone and aripiprazole are second
generation antipsychotics，but have different pharmacological effects of antipsychotic
treatment.This study was designed to examine the acute efficacy, safety, and tolerability of
risperidone and aripiprazole for patients with MAP.